Wolverine BlendWhat the studies show

The BPC-157 record is mostly rats. In a 2003 study, rats with a cut Achilles tendon that were given BPC-157, by injection or by mouth, had tendons that were stronger and better organised at every time point than rats given saline ³. The Zagreb group's 2011 review collects dozens of other rat models from the same laboratory: crushed muscle that recovered function sooner, stomach lining protected from alcohol and anti-inflammatory drugs, bowel injuries that closed ¹.

A 2017 study from Taiwan supplied a mechanism. BPC-157 increased the growth of new blood vessels in rat tissue and in cultured vessel-lining cells, acting through VEGFR2, the main receptor that tells those cells to multiply; blocking the receptor removed the effect ⁴. There is no completed, placebo-controlled trial of BPC-157 in people ¹.

The thymosin beta-4 record is wider and slightly older, and nearly all of it used the full protein rather than the fragment. In 1999, full-thickness wounds on rats closed faster when thymosin beta-4 was applied to the wound or injected, with more collagen and more new vessels in the wound bed ⁵. In 2003 the same NIH group tested the seven-amino-acid actin-binding piece alone and found that it made vessel-lining cells attach and migrate in a dish and drove new vessel sprouts from rings of rat aorta, much as the whole protein did ².

The full protein has reached small human trials, but for the eye: in a 2015 randomized trial, 72 people with severe dry eye received 0.1% thymosin beta-4 drops or placebo for 28 days, and the treated group had less corneal surface damage ⁶. Nothing in people has looked at tendons or muscle.

Read side by side, the two records overlap at one point: both molecules pushed the growth of new blood vessels, BPC-157 through VEGFR2 ⁴ and the thymosin beta-4 fragment through the movement of vessel-lining cells ². Those are different mechanisms, which is the basis of the claim that they might add up. But a claim is all it is. There is no published study, in animals, cells or people, that gave BPC-157 and thymosin beta-4 or its fragment together and compared the result with either one alone. No one has measured whether the pair adds, cancels or does nothing extra, and no one has looked at what two separate sets of side effects do in combination.

Neither peptide is an approved medicine in any country. The human record for the pair comes down to this: one half with no trial at all, the other half with eye-drop trials of a different form of the molecule, and nothing on the two together.